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ABSTRACT
Background: CC chemokines have been shown to play an important role in inducing selective recruitment of
inflammatory cells into local allergic inflammatory sites. CC chemokines are also known as histamine releasing
factors. We previously showed that histamine enhances transcription of CC chemokines from nasal mucosa
which leads to further induction of histamine release. This cyclic cascade may cause prolonged allergic inflam-
mation. The aim of this study is to clarify the relationship between histamine and CC chemokine production by
using human nasal epithelial cells (HNECs) and to examine the potential of H1 receptor (H1R) antagonists in
new therapeutic approaches for the treatment of nasal allergy.
Methods: HNECs were isolated from the nasal turbinates of patients diagnosed with nasal allergy. HNEC
monolayers were cultured for 48 hours with or without histamine (10−3 to 10−5 molL). Furthermore, an H1R an-
tagonist, either carebastine or olopatadine, was added to the supernatant (10−3 to 10−7 molL) 30 minutes be-
fore incubation with histamine. The expression of Regulated on Activation, Normal T-cell Expressed and Se-
creted (RANTES) and monocyte chemotactic protein-1 (MCP-1) in the culture media were measured by ELISA.
Results: The release of RANTES and MCP-1 was significantly upregulated by histamine compared with the
control group. Both carebastine and olopatadine inhibited the release of CC chemokine production to the con-
trol level in both groups.
Conclusions: This study suggests that the interaction between histamine and CC chemokines may prolong
allergic inflammation in human nasal mucosa. We also demonstrate the potential use of H1R antagonists in
new therapeutic approaches to the treatment of nasal allergy through inhibiting this histamine-CC chemokine
interaction.
KEY WORDS
allergic rhinitis, carebastine, CC chemokine, histamine, human nasal epithelial cells, monocyte chemotactic
protein-1, olopatadine, RANTES
INTRODUCTION
Allergic rhinitis, one of the typical type I immuno-
allergic reactions, has been well studied and its
pathophysiologic mechanisms are unraveling. The
immediate phase response during allergic rhinitis is
associated with IgE-mediated mast cell activation and
results in the release of primary inflammatory media-
tors, which cause sneezing and rhinorrhea. The early
phase of an allergic reaction is followed by the late
phase reaction characterized by selective recruitment
of inflammatory cells, particularly eosinophils and ba-
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sophils. The pathogenesis of the late phase reaction
is so complicated that the precise mechanism of in-
flammatory cell recruitment is not yet fully under-
stood. Results from several studies have led investiga-
tors to conclude that CC chemokines, including
monocyte chemotactic protein (MCP)-1, MCP-3,
Regulated on Activation, Normal T-cell Expressed
and Secreted (RANTES), and eotaxin, may play an
important role in inducing selective recruitment of
these cells to the allergic inflammatory site.1 On the
other hand, histamine is generally recognized as an
important mediator of allergic rhinitis.2 Histamine is
released from mast cells in the immediate phase and
basophils in the late phase.3,4 It is also reported that
histamine induces production and expression of vari-
ous cytokines5 and adhesion molecules.6 Previously,
we showed, using the reverse transcription-
polymerase chain reaction (RT-PCR) technique that
in the nasal mucosa upregulated the mRNA expres-
sion of CC chemokines, MCP-1, MCP-3, RANTES
and eotaxin.7 We also demonstrated that the hista-
mine H1 receptor antagonist carebastine inhibited
this upregulation. These results led us to the hy-
pothesis that histamine may induce CC chemokine
production of histamine in nasal mucosa and may
form a prolonged inflammatory cycle in the
histamine-CC chemokine axis in allergic rhinitis. The
aim of this study is to prove the relationship between
histamine and CC chemokine more precisely by us-
ing human nasal epithelial cells. Moreover, we exam-
ined the anti-inflammatory effect of antihistamines
and accumulated more findings, which support the
clinical efficiency and potential of these agents for




Carebastine and olopatadine, H1R antagonists, were
kindly provided by Dainippon Sumitomo Pharmaceu-
tical Co., Ltd. (Osaka, Japan) and Kyowa Hakko
Kogyo Co., Ltd. (Tokyo, Japan), respectively.
PATIENTS
Twenty-two patients with allergic rhinitis who under-
went turbinectomy for the treatment of nasal obstruc-
tion (13 men and 9 women, range 12 to 58 years;
26.59 ± 11.19 years [mean ± SEM]) were included in
this study. All patients had severe symptoms of nasal
obstruction due to irreversible changes in the inferior
turbinate or deflected nasal septum. All patients had
positive allergy responses for mite nasal allergy, de-
termined by a clinical history, a nasal smear positive
for eosinophils, positive intradermal testing, or serum
specific mite IgE antibodies (CAP system, Pharmacia
Diagnosis, Sweden), as well as positive nasal provoca-
tion test responses and negative test responses for
other common aeroallergens. All patients refrained
from taking topical corticosteroids for four weeks and
from taking anti-histamines for two weeks prior to the
study. The patients who were treated with immuno-
therapy were not included in this study. This study
was approved by the Nippon Medical School’s Ethics
Committee and informed consent was obtained from
all patients who participated in this research.
PREPARATION OF EXPLANT CULTURE WITH
HUMAN NASAL EPITHELIAL CELLS
Epithelial cells of the nasal inferior turbinate were ob-
tained from surgically resected nasal turbinate and
dispersed as previously described by Otsuka et al..8
Briefly, after incubation in McCoy’s 5A (GIBCO BRL:
Grand Island, NY, USA) with 0.1% protease E (Quan-
tikine Co., Minneapolis, MN, USA) at 4℃ for 24
hours, epithelial cells were detached from the tur-
binate tissue by gentle agitation. Human nasal epithe-
lial cells (HNECs) were cultured until they reached
confluence (5―7days) in type I collagen coated 24
well tissue culture plates under a humidified atmos-
phere at 37℃ and 5% CO2. Confluent cells, with a vi-
ability greater than 90% measured by trypan blue ex-
clusion, were then incubated for 48 hours in serum-
free McCoy’s 5A medium with and without various
concentrations (10−5 to 10−3 molL) of histamine dihy-
drochloride (ICN Biomedicals, Inc, Aurora, OH,
USA). To investigate the effect of the histamine H1
receptor antagonists on CC chemokine expression,
cells were pre-incubated in the medium containing
10−7 to 10−5 molL carebastine or olopatadine for 30
minutes before histamine was added. In the control
group, cells were incubated with carebastine or olo-
patadine only.
ANALYSIS OF MCP-1 AND RANTES PRODUC-
TION
MCP-1 and RANTES production in prepared superna-
tant was examined using an immunoassay kit (R&D
Systems, Inc., Minneapolis, MN, USA). The detection
limit of MCP-1 was 5.0 pgml and that of RANTES
was 2.0 pgml. The percent changes of these values
by histamine or H1R antagonists were calculated.
Samples were prepared in duplicate in accordance
with the manufacturer’s directions.
STATISTICAL ANALYSIS
The data are expressed as means ± SEM. The statisti-
cal significance of differences among groups were
analyzed by one way ANOVA and subsequently by
the Tukey-Kramer’s analysis. StatView J-5.0 software
(SAS Institute Inc., Cary, NC, USA) was used in all
statistical analyses. The differences were considered
significant only when the p value was less than 0.05.
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Fig. 1 The efect of histamine on CC chemokine produc-
tion from HNECs. The expression of MCP-1 or RANTES in 
the culture media was measured by enzyme-linked immuno-
adsorbent assay (ELISA). a) Histamine tended to upregu-
late MCP-1 expression dose-dependently and the percent 
changes of MCP-1 production were increased significantly 
by 10 －3 mol/L of histamine, compared with the non-hista-
mine control (p＜0.05). b) The percent changes of expres-
sion of RANTES from HNECs were significantly up-
regulated by 10 －3 mol/L of histamine (p＜0.05). The produc-
tion of RANTES also tended to be up-regulated by hista-
mine in a dose-dependent manner.
Fig. 2 The efect of carebastine alone on chemokines 
expression. a) The expression of MCP-1 from HNECs was 
not afected by carebastine. b) The expression of RANTES 
from HNECs was not afected by carebastine.
a) MCP-1
b) RANTES
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BASAL CC CHEMOKINE EXPRESSION BY HIS-
TAMINE STIMULATION
The baseline production of MCP-1 was 4140.8 ±
3925.4 pgml. MCP-1 expression in HNECs was sig-
nificantly upregulated to 137.3 ± 33.9% by 10−3 molL
of histamine (p < 0.05) (Fig. 1a).
The baseline production of RANTES was 16.5 ±
11.11 pgml. As showed in Figure 1b, the expression
in HNECs of RANTES was significantly upregulated
by histamine in a dose-dependent manner (10−3 mol
L and 10−4 molL; 152.7 ± 33.9 %, and 153.6 ± 51.3% re-
spectively) (p < 0.05).
INHIBITORY EFFECT OF CAREBASTINE OR
OLOPATADINE ON HISTAMINE-STIMULATED
PRODUCTION OF CC CHEMOKINES
The expression of MCP-1 or RANTES in HNECs was
not affected by either carebastine or olopatadine
alone (Figs. 2, 3).
Carebastine significantly inhibited histamine-
stimulated production of MCP-1 and RANTES in
HNECs (Fig. 4 respectively) (p < 0.05). The produc-
tion of MCP-1 and RANTES, stimulated with hista-
mine, was inhibited by carebastine in a dose-
dependent manner. 10−5 molL of carebastine de-
creased MCP-1 secretion to 70.0 ± 13.5%, while 10−6
molL decreased MCP-1 secretion to 73.4 ± 19.9%.
Also RANTES was reduced to 71.9 ± 26.3% by 10−5
molL of carebastine and to 73.2 ± 24.9% by 10−6 mol
L of carebastine. In a manner similar to carebastine,
olopatadine significantly decreased MCP-1 or RAN-
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Fig. 3 Efect of olopatadine alone on chemokines expression.
a, b) The expression of MCP-1 or RANTES in HNECs was 
not afected by olopatadine alone.
















Fig. 4 The efect of carebastine on expression of chemoki-
nes with histamine. HNECs were preincubated in the me-
dium with carebastine, previous to histamine addition. MCP-
1 or RANTES expression was measured by ELISA. a) Care-
bastine dose-dependently inhibited the stimulatory efect of 
histamine on MCP-1 production from HNECs (histamine (10
 －3 M)/histamine with carebastine (10 －5 M): p＜ 0.05, hista-
mine (10 －3 M)/histamine with carebastine (10 －6 M): p＜
0.05). b) Carebastine also dose-dependently inhibited the 
enhanced expression of RANTES with histamine stimulation 
(histamine (10 －3 M)/histamine with carebastine (10 －5 M): p
＜0.05, histamine (10 －3 M)/histamine with carebastine (10 －6 
M): p＜0.05).
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TES (Fig. 5) secretion in HNECs in a dose-dependent
manner. 10−5 molL of olopatadine decreased MCP-1
secretion to 78.9±22.1%, while 10−6 molL decreased
MCP-1 secretion to 79.0±16.7%. Also RANTES was re-
duced to 77.5±16.1% by 10−5 molL of olopatadine to
77.0±12.4% by 10−6 molL of olopatadine and to 77.9±
13.1% by 10−7 molL of olopatadine.
DISCUSSION
Nasal epithelial cells are major cell sources of pro-
inflammatory cytokines and chemokines,1,9 which
contribute to the pathogenesis of nasal allergy. Sev-
eral studies have shown that histamine induces secre-
tion of various inflammatory cytokines from airway
epithelial cells.10-14 Moreover, histamine has also
been reported to activate endothelial cells and bron-
chial epithelial cells to express adhesion molecules.15
Consequently, the logical question was raised as to
whether H1-receptor antagonists could affect these
up-regulatory effects of histamine on nasal epithelial
cells. Some of the new generation H1-antihistamines,
olopatadine, fexofenadine, levocabastine, and
emedastine, have been reported as having several
anti-inflammatory effects including down-regulation
of pro-inflammatory cytokines and chemokines pro-
duction from conjunctival, nasal, and bronchial epi-
thelial cells in vitro.11,14,16,17 However, the mechanism
of the anti-inflammatory effects of these new genera-
tion H1-antihistamines have not been fully under-
stood yet. Although our previous study suggests the
presence of H1 receptors in nasal mucosal tissue, mu-
cosal tissue might contain epithelium and fewer other
cells such as fibroblasts and endothelial cells. In this
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Fig. 5 The efect of olopatadine on expression of chemoki-
nes with histamine. As with experiments involving carebasti-
ne, olopatadine was added to the medium in advance of 
histamine stimulation of HNECs. Expression of chemokines 
was assessed by ELISA. a) Olopatadine significantly de-
creased MCP-1 production with histamine in a dose-depend-
ent manner (histamine (10 －3 M)/histamine with olopatadine 
(10 －5 M): p＜ 0.05, histamine (10 －3 M)/histamine with olo-
patadine (10 －6 M) : p＜0.05). b) Olopatadine dose-depen-
dently decreased RANTES production from HNECs 
(histamine (10 －3 M)/histamine with olopatadine (10 －5M): p＜
0.05, histamine (10 －3 M)/histamine with olopatadine (10 －6 
M): p＜0.05, histamine (10 －3 M)/histamine with olopatadine 
(10 －7 M): p＜0.05).
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study, our findings, together with the evidence pre-
sented by other studies using the RT-PCR technique,
suggest that the nasal epithelium expresses hista-
mine H1 receptors.18-20 The autoradiographic studies
by Okayama et al. on human nasal turbinate mucosa
failed to demonstrate the presence of H1 receptors in
epithelium.21 Given this controversy, the localization
of H1 receptors in human nasal mucosa needs to be
more fully clarified in future investigations.
CC chemokines have been shown to play an impor-
tant role in inducing selective recruitment of inflam-
matory cells, especially eosinophils and basophils,
into local allergic inflammatory sites.1,22-26 Previously
we demonstrated that CC chemokines act as a hista-
mine releasing factor and are up-regulated by hista-
mine.7,27 By forming this prolonged inflammatory cy-
cle, the histamine-CC chemokine interaction may
contribute to the protraction of nasal allergy. Addi-
tionally, this reaction may cause subsequent infiltra-
tion of inflammatory cells. In this study, we demon-
strated that the newly generated antihistamines
ebastine and olopatadine may inhibit the formation of
this inflammatory cycle. Fexofenadine decreased con-
stitutive and eosinophil-induced release of RANTES
from nasal epithelial cells, but this decrease was not
statistically significant.17 Loratadine decreased NO2-
induced release of RANTES from bronchial epithelial
cells. 28 Several investigators reported down-
regulation of IL-8,29,30 which is a CXC-chemokine. As
described above, newly generated antihistamines are
known to have anti-inflammatory effects. We selected
olopatadine and ebastine for use in this study as a fo-
cus for future clinical investigation, due to the fact
that they are commonly being used as a new genera-
tion of antihistamines in Japan.
These new generation antihistamines are able to ef-
fectively antagonize H1 receptors expressed in the
human nose. Some of them have additional proper-
ties, in particular anti-inflammatory activities that may
be linked to their action on H1-receptors. Church has
suggested that many of these anti-inflammatory prop-
erties require 10 to 1000 times higher doses than
those used for symptom relief in allergic rhinitis or
urticaria.31 In our study, both carebastine and olo-
patadine inhibited histamine-induced upregulation of
CC chemokines at concentrations which were not far
from those used clinically (about 2 to 5 times higher).
This benefit may demonstrate one therapeutic option
for treating allergic rhinitis. Recently, several studies
have confirmed the anti-inflammatory properties of
antihistamine in vivo but failed to demonstrate the
down-regulation of pro-inflammatory cytokines or
chemokines.32-34
In this study, we used 10−3 molL of histamine to
activate nasal epithelial cells to evaluate the down-
regulatory effects of anti-histamines. Jeannin et al.12
reported that the concentration of histamine after
mast cell degranulation in nasal tissue was 10−6 to
10−4 molL, however, the nasal epithelial cells were
located very close to the mast cells in the nasal tissue.
Consequently, we considered 10−3 molL of hista-
mine as a reasonable concentration for activation of
nasal epithelial cells. We concluded that it was very
meaningful that both carebastine and olopatadine, in
dosages close to clinical use, successfully inhibited
chemokine production of nasal epithelial cells even
when stimulated by such high concentrations of his-
tamine.
Definitive evidence regarding whether the anti-
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inflammatory effects of antihistamines are H1-
receptor mediated or has not been shown yet. Al-
though inhibition of calcium influx in cells and NF-κB
activation are thought to be involved,35 precise
mechanisms underlying these anti-inflammatory ef-
fects are not well understood. Furthermore, it has not
been determined whether the observed anti-
inflammatory effects of each antihistamine are drug
specific or a property common to all of them. Our
findings that blockade of the H1 receptor in nasal mu-
cosa down-regulates histamine-induced expression of
CC chemokines reflects a simple mechanism and
seems to be a common property of antihistamines. To
resolve these important issues, more careful investi-
gations are needed in the future.
Uncontrolled allergic rhinitis leads to worsening of
coexisting asthma and, conversely, treatment of aller-
gic rhinitis improves coexisting asthma. Relief of in-
flammation is important for the management of both
disorders. Orally administrated H1-antihistamine, in
the doses ordinarily used for allergic rhinitis, im-
proved coexisting mild seasonal asthma symptoms. It
has been demonstrated that minimal persistent in-
flammation exists in patients with allergic rhinitis,
even in the absence of clinically active symptoms.36
This concept suggests the need for long-term anti-
inflammatory treatment to adequately control allergic
disorders.37 The Consensus Group on New Genera-
tion Antihistamines (CONGA) recommended that the
anti-allergic properties of antihistamines should be
demonstrable in vivo, in humans, at therapeutic
doses and under natural exposure to the offending al-
lergens.38 In our study, the anti-inflammatory proper-
ties of ebastine and olopatadine were demonstrated
in humans, at doses which are not far above the
therapeutic doses. Although an in vivo study in hu-
mans would not be easy to design and carry out, the
results of our study suggest that it would be meaning-
ful to carry out an in vivo study in the near future.
Antihistamines may produce anti-inflammatory ef-
fects through blocking histamine and CC chemokine
interaction. These effects lead to reduction of the pro-
longed inflammatory allergic cycle. The results of this
study suggest that continuous treatment with antihis-
tamines will be useful in reducing basal levels of aller-
gic inflammation. Further investigations regarding
the size, term, and method of administration of an ef-
fective antihistamine dose are required.
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